tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Crinetics Pharmaceuticals: Phase 2 TouCAHn De‑Risking and Optimized Phase 3 Design Drive Upgrade to Buy and $67 Target
PremiumRatingsCrinetics Pharmaceuticals: Phase 2 TouCAHn De‑Risking and Optimized Phase 3 Design Drive Upgrade to Buy and $67 Target
1M ago
Crinetics upgraded to Buy from Neutral at Goldman Sachs
Premium
The Fly
Crinetics upgraded to Buy from Neutral at Goldman Sachs
1M ago
Crinetics price target raised to $87 from $80 at Morgan Stanley
Premium
The Fly
Crinetics price target raised to $87 from $80 at Morgan Stanley
2M ago
Crinetics rises 12.8%
PremiumThe FlyCrinetics rises 12.8%
2M ago
Crinetics 7.62M share Secondary priced at $45.95
Premium
The Fly
Crinetics 7.62M share Secondary priced at $45.95
2M ago
Crinetics Highlights Strong PALSONIFY Launch and Trial Progress
Premium
Company Announcements
Crinetics Highlights Strong PALSONIFY Launch and Trial Progress
2M ago
Crinetics (CRNX): Robust Atumelnant CAH Data, De-Risked Phase 3, and Strong Execution Underpin Buy Rating
PremiumRatingsCrinetics (CRNX): Robust Atumelnant CAH Data, De-Risked Phase 3, and Strong Execution Underpin Buy Rating
2M ago
Crinetics price target raised to $90 from $80 at Evercore ISI
Premium
The Fly
Crinetics price target raised to $90 from $80 at Evercore ISI
2M ago
RBC Capital would be a buyer of Neurocrine on weakness following competitor data
Premium
The Fly
RBC Capital would be a buyer of Neurocrine on weakness following competitor data
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100